You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for QNZ 46
QNZ 46 is a GluN2C/GluN2D-selective NMDA receptor non-competitive antagonist (IC50 values are 3, 6, 229, and >300, >300 μM for GluN2D, GluN2C, GluN2A, GluN2B, and GluR1, respectively). Requires binding of glutamate to the GluN2 subunit.
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
Technical Data for QNZ 46
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for QNZ 46
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|DMSO||4.43||10 with gentle warming|
Preparing Stock Solutions for QNZ 46
The following data is based on the product molecular weight 443.41. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||22.55 mL||112.76 mL||225.52 mL|
|0.5 mM||4.51 mL||22.55 mL||45.1 mL|
|1 mM||2.26 mL||11.28 mL||22.55 mL|
|5 mM||0.45 mL||2.26 mL||4.51 mL|
References for QNZ 46
References are publications that support the biological activity of the product.
Mosley et al (2010) Quinazolin-4-one derivatives: A novel class of noncompetitive NR2C/D subunit-selective N-MthD.-aspartate receptor antagonists. J.Med.Chem. 53 5476 PMID: 20684595
Hansen and Traynelis (2011) Structural and mechanistic determinants of a novel site for noncompetitive inhibition of GluN2D-containing NMDA receptors. J.Neurosci. 31 3650 PMID: 21389220
If you know of a relevant reference for QNZ 46, please let us know.
View Related Products by Product Action
Keywords: QNZ 46, QNZ 46 supplier, QNZ46, Glu, NR2C, NR2D, antagonists, glutamate, NMDA, receptors, GluN2C, GluN2D, Receptors, 4801, Tocris Bioscience
1 Citation for QNZ 46
Citations are publications that use Tocris products. Selected citations for QNZ 46 include:
Brancaccio et al (2017) Astrocytes Control Circadian Timekeeping in the Suprachiasmatic Nucleus via Glutamatergic Signaling. Neuron 93 1420 PMID: 28285822
Do you know of a great paper that uses QNZ 46 from Tocris? Please let us know.
Reviews for QNZ 46
There are currently no reviews for this product. Be the first to review QNZ 46 and earn rewards!
Have you used QNZ 46?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.